Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial

Filename 166. Siebenhaar et al, Rup. improves QoL in mastoc. SMART ALLERGY 2013.pdf
Filesize 305.55 KB
Version o.166
Date added June 5, 2020
Downloaded 0 times
Category Original Work
Tags Antihistamine, mastocytosis, platelet-activating factor, rupatadine, urticaria pigmentosa
Authors Siebenhaar, F., Förtsch, A., Krause, K., Weller, K., Metz, M., Magerl, M., Martus, P., Church, M. K., and Maurer, M.
Citation Siebenhaar, F., Förtsch, A., Krause, K., Weller, K., Metz, M., Magerl, M., Martus, P., Church, M. K., and Maurer, M.: Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013: 68; 949-952.
Corresponding authors Siebenhaar, F.
DocNum O.166
DocType PDF
Edition; Page 68; 949-952
IF 5.99
Publisher Allergy
ReleaseDate 2013

Background: Mastocytosis is frequently associated with mast cell-mediated symp- toms which require relieving medication. While second generation antihistamines (sgAHs) are the first line therapeutic strategy to treat mast cell mediator-related symptoms, controlled clinical trials on how they improve quality of life have not been performed.

Methods: This randomized, double-blind, placebo-controlled, cross-over trial assessed rupatadine 20 mg daily in the treatment of mastocytosis symptoms in 30 adult patients. Symptoms were assessed by a visual analogue scale (VAS) and symptom specific quality of life questionnaire (ItchyQoL).

Results: The mean ItchyQoL total score and VAS symptom score were signifi- cantly improved in the rupatadine treatment phase compared with placebo. There were also significant reductions from placebo in the severity of itch, wheal and flare, flushing, tachycardia and headache but not gastrointestinal symptoms. Conclusions: In this first comprehensive trial of a sgAH in mastocytosis, rupata- dine 20 mg daily for 4 weeks significantly controlled symptoms and improved patients’ quality of life.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.